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2Craniofacial Osteoradionecrosis (ORN) represents a late complication of radiotherapy (RT) for
head and neck cancer. Traditionally, mandibular ORN refers to the RT-related mandible
necrosis and subsequent exposure of the bone for at least 3 months in the absence of recurrence
(1). We now have increasing evidence of long-term  tissue damage from chemo-radiation (2,3).
Most of cases are diagnosed between 1 to 2 years following RT but there is lifelong risk (2).
Caparroti et al recently reported that the actuarial rate of ORN of the mandible was 3% at 1
year, 5% at 3 years, and 7% at 5 years in 1196 patients who were diagnosed with squamous
cell carcinoma of the oropharynx and treated with curative-intent radiotherapy, with or without
concomitant systemic treatment, from January 2005 to December 2014.  As the proportion of
HPV- related oropharyngeal cancer treated with chemo- RT is soaring, and it mainly affects
young non- smoker individuals, ‘at risk’ population has significantly increased necessitating
better understanding, and management of the disease (5).
ORN is characterized by hypoxic, hypocellular and hypovascular tissue, followed by tissue
breakdown secondary to radiation-induced activation and dysregulation of the fibroblastic
activity that caused vascular fibrosis and thrombosis. The mandible is more susceptible to ORN
as it is solely supplied by the paired inferior alveolar arteries; therefore, the obliteration of its
nutrient vessels causes an ischemic necrosis in irradiated atrophic tissue. Due to this relatively
poor vascularization and the absence of collateral blood supply, the mandible, especially buccal
cortex of premolar, molar and retromolar regions, is at greater risk of necrosis (3).
It has been suggested that post-RT dental extractions, especially of posterior lower teeth, or
dental implant placement are the main culprits (although we are lacking level I evidence), but
ORN can also occur spontaneously. The recommended dose constraint is a maximum dose of
70Gy. However, it is generally accepted that the risk of ORN is high at dose >60 Gy, moderate
between 40 and 60 Gy, and null <40 Gy, and that there is a dimension-dose correlation: lesions
>2 cm occurred at doses>60 Gy, whereas lesions <2 cm in size are related to doses <60 Gy (3).
The clinical spectrum of disease ranges from the asymptomatic exposure to debilitating pain,
extra-oral fistulae and pathological fracture. In line with the onset and severity of clinical
symptoms and radiological findings several classification systems have been proposed, and
treatment varies from clinical surveillance to major reconstructive surgery with composite free
flaps.
As mentioned above, several ORN classification systems have proposed. Shaw et al. recently
reviewed 16 ORN classifications and considered Notani classification with the addition of
3minor  bone  spicules  as  the  most  reliable  and  consistent  in  terms  of  reporting  ORN  for
prospective clinical trials (5,6). In addition, Notani et al proposed treatment based on the height
of mandible that is affected (Table 1).
Most clinicians and researchers will use the Notani classification for communicating a patient’s
condition and for the reporting in clinical trials. Indeed, this is a step forwards but can also be
misleading implying that the mandible is the primary and exclusive site of ORN. Nonetheless,
a group of patients are now emerging, with a history of chemo-radiation for head and neck
cancer with mandibular ORN and additional involvement of adjacent craniofacial skeleton and
its underlying structures. In this context temporal or frontal bone ORN with TMJ destruction,
extra-intraparenchymal brain collections, middle ear otitis/mastoiditis and facial palsy can be
encountered. These patients are difficult to classify using the Notani or other available
classifications (Picture 1).
Patients with isolated mandibular ORN are often challenging pertained to their reconstructive
problems, but overall their aesthetics and function can be restored with free tissue transfer
resulting in an acceptable health related quality of life (HRQOL). In contrast the patient with
mandibular ORN in addition to the sites described above often have dismal prognosis and
invariably have signs and symptoms that are very difficult to manage; often are not amenable
to surgery and may succumb to their complications. We recommend the addition of ‘’end stage
disease’’, to include cases with Notani stage III and additional regional involvement as per
Table 2.
Table 1. The Notani classification for mandibular ORN
4Stage I ORN confined to the alveolar bone.
Stage II ORN limited to the alveolar bone and/or the mandible above the level of
the mandibular alveolar canal.
Stage III ORN that extended to the mandible under the level of the mandibular alveolar
canal and ORN with a skin fistula and/or a pathologic fracture.
Table 2. Features of ‘end-stage’ ORN
End stage ORN Mandibular Notani III plus any of the
following:
x Fronto-Zygomatic-Orbital Complex
involvement
x Skull base bone destruction with
middle ear involvement (with or
without VIIth or other cranial nerve
involvement) or TMJ involvement
with destruction of fossa and
temporal bone
x Extradural abscess, Subdural
Empyema or Brain abscess
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Figure 1. Extensive ORN involving the mandible and base of skull (please see arrow)
6Figure 2. Extensive ORN involving the mandible and temporal bone and subdural collection
(please see arrow)
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